Celularity Closes Transaction with NexGel to Monetize Biomaterials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CELU?
Source: Newsfilter
- Transaction Overview: Celularity's transaction with NexGel totals $13.3 million, comprising $8.3 million in cash and a $5.0 million convertible note, aimed at monetizing biomaterials assets to strengthen the company's capital structure.
- Future Revenue Potential: Celularity stands to receive up to $20.0 million in future milestone payments based on net sales thresholds, along with royalties from certain development-stage products, which could significantly enhance its financial performance.
- Debt Reduction Impact: The transaction enables Celularity to retire nearly $13.0 million in debt, markedly improving its balance sheet and capital position, thereby supporting future strategic investments.
- Strategic Focus Adjustment: By streamlining its biomaterials activities through this transaction, Celularity aims to concentrate on its longevity-focused therapeutic pipeline, optimizing resource allocation to enhance the development efficiency of high-value cellular therapeutics and drive long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELU
About CELU
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celularity Closes Transaction with NexGel to Monetize Biomaterials
- Transaction Overview: Celularity's transaction with NexGel totals $13.3 million, comprising $8.3 million in cash and a $5.0 million convertible note, aimed at monetizing biomaterials assets to strengthen the company's capital structure.
- Future Revenue Potential: Celularity stands to receive up to $20.0 million in future milestone payments based on net sales thresholds, along with royalties from certain development-stage products, which could significantly enhance its financial performance.
- Debt Reduction Impact: The transaction enables Celularity to retire nearly $13.0 million in debt, markedly improving its balance sheet and capital position, thereby supporting future strategic investments.
- Strategic Focus Adjustment: By streamlining its biomaterials activities through this transaction, Celularity aims to concentrate on its longevity-focused therapeutic pipeline, optimizing resource allocation to enhance the development efficiency of high-value cellular therapeutics and drive long-term growth.
See More
Celularity Faces Nasdaq Compliance Issue
- Compliance Notice: Celularity received a notice from Nasdaq on April 16, 2026, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K for the fiscal year ending December 31, 2025, which could jeopardize its listing status.
- Compliance Plan Deadline: Under Nasdaq rules, the company has 60 calendar days from the notice to submit a compliance plan, and if accepted, it may receive up to 180 days from the original Form 10-K due date to regain compliance.
- Financial Impact: The compliance issue has led to a 0.81% drop in Celularity's shares, which may negatively affect investor confidence and the company's ability to raise funds.
- Strategic Licensing Agreement: Despite facing compliance challenges, Celularity secured a strategic licensing deal worth up to $35 million for its biomaterials portfolio, indicating potential growth opportunities in the market.
See More
CELULARITY RECEIVES NASDAQ NOTICE FOR DELAYED FORM 10-K FILING
- Company Announcement: Cellularity has announced the receipt of a notice from NASDAQ regarding a late filing of its Form 10-K.
- Regulatory Compliance: The notice indicates that Cellularity did not meet the deadline for submitting its annual report, which is a requirement for maintaining its listing on NASDAQ.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Closes Transaction with NexGel to Monetize Biomaterials
- Transaction Overview: Celularity's transaction with NexGel totals $13.3 million, comprising $8.3 million in cash and a $5.0 million convertible note, aimed at monetizing biomaterials assets to strengthen the company's capital structure.
- Future Revenue Potential: Celularity stands to receive up to $20.0 million in future milestone payments based on net sales thresholds, along with royalties from certain development-stage products, which could significantly enhance its financial performance.
- Debt Reduction Impact: The transaction enables Celularity to retire nearly $13.0 million in debt, markedly improving its balance sheet and capital position, thereby supporting future strategic investments.
- Strategic Focus Adjustment: By streamlining its biomaterials activities through this transaction, Celularity aims to concentrate on its longevity-focused therapeutic pipeline, optimizing resource allocation to enhance the development efficiency of high-value cellular therapeutics and drive long-term growth.
See More
Celularity Faces Nasdaq Compliance Issue
- Compliance Notice: Celularity received a notice from Nasdaq on April 16, 2026, regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-K for the fiscal year ending December 31, 2025, which could jeopardize its listing status.
- Compliance Plan Deadline: Under Nasdaq rules, the company has 60 calendar days from the notice to submit a compliance plan, and if accepted, it may receive up to 180 days from the original Form 10-K due date to regain compliance.
- Financial Impact: The compliance issue has led to a 0.81% drop in Celularity's shares, which may negatively affect investor confidence and the company's ability to raise funds.
- Strategic Licensing Agreement: Despite facing compliance challenges, Celularity secured a strategic licensing deal worth up to $35 million for its biomaterials portfolio, indicating potential growth opportunities in the market.
See More
CELULARITY RECEIVES NASDAQ NOTICE FOR DELAYED FORM 10-K FILING
- Company Announcement: Cellularity has announced the receipt of a notice from NASDAQ regarding a late filing of its Form 10-K.
- Regulatory Compliance: The notice indicates that Cellularity did not meet the deadline for submitting its annual report, which is a requirement for maintaining its listing on NASDAQ.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
